# Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer

> **NCT00300781** · PHASE2 · COMPLETED · sponsor: **Puma Biotechnology, Inc.** · enrollment: 136 (actual)

## Conditions studied

- Breast Neoplasms
- Neoplasms

## Interventions

- **DRUG:** neratinib

## Key facts

- **NCT ID:** NCT00300781
- **Lead sponsor:** Puma Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08-04
- **Primary completion:** 2008-04
- **Final completion:** 2018-01-30
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2018-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00300781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00300781, "Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00300781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*